BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34624527)

  • 1. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
    Kurhe Y; Caputo M; Cansby E; Xia Y; Kumari S; Anand SK; Howell BW; Marschall HU; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):405-423. PubMed ID: 34624527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STK25 is a critical determinant in nonalcoholic steatohepatitis.
    Amrutkar M; Chursa U; Kern M; Nuñez-Durán E; Ståhlman M; Sütt S; Borén J; Johansson BR; Marschall HU; Blüher M; Mahlapuu M
    FASEB J; 2016 Oct; 30(10):3628-3643. PubMed ID: 27421788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
    Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
    FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
    Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
    J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver.
    Nerstedt A; Kurhe Y; Cansby E; Caputo M; Gao L; Vorontsov E; Ståhlman M; Nuñez-Durán E; Borén J; Marschall HU; Mashek DG; Saunders DN; Sihlbom C; Hoy AJ; Mahlapuu M
    J Lipid Res; 2020 Feb; 61(2):178-191. PubMed ID: 31857389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
    Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
    Suzuki-Kemuriyama N; Abe A; Nakane S; Yuki M; Miyajima K; Nakae D
    PLoS One; 2023; 18(8):e0287657. PubMed ID: 37535625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
    Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
    Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
    He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M
    J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.
    Kumar DP; Santhekadur PK; Seneshaw M; Mirshahi F; Uram-Tuculescu C; Sanyal AJ
    Hepatology; 2019 Apr; 69(4):1520-1534. PubMed ID: 30394550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-21-5p promotes NASH-related hepatocarcinogenesis.
    Rodrigues PM; Afonso MB; Simão AL; Islam T; Gaspar MM; O'Rourke CJ; Lewinska M; Andersen JB; Arretxe E; Alonso C; Santos-Laso Á; Izquierdo-Sanchez L; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Prip-Buus C; Banales JM; Rodrigues CMP; Castro RE
    Liver Int; 2023 Oct; 43(10):2256-2274. PubMed ID: 37534739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
    Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
    Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
    [No Abstract]   [Full Text] [Related]  

  • 16. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
    Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P
    Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.
    Ye J; Li TS; Xu G; Zhao YM; Zhang NP; Fan J; Wu J
    Cancer Res; 2017 Oct; 77(19):5287-5300. PubMed ID: 28775168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase STK25 controls lipid partitioning in hepatocytes and correlates with liver fat content in humans.
    Amrutkar M; Kern M; Nuñez-Durán E; Ståhlman M; Cansby E; Chursa U; Stenfeldt E; Borén J; Blüher M; Mahlapuu M
    Diabetologia; 2016 Feb; 59(2):341-53. PubMed ID: 26553096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
    Kessler SM; Simon Y; Gemperlein K; Gianmoena K; Cadenas C; Zimmer V; Pokorny J; Barghash A; Helms V; van Rooijen N; Bohle RM; Lammert F; Hengstler JG; Mueller R; Haybaeck J; Kiemer AK
    Int J Mol Sci; 2014 Apr; 15(4):5762-73. PubMed ID: 24714086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.